• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿曲库铵:预防组胺释放及减轻血流动力学反应的临床策略。

Atracurium: clinical strategies for preventing histamine release and attenuating the haemodynamic response.

作者信息

Scott R P, Savarese J J, Basta S J, Sunder N, Ali H H, Gargarian M, Gionfriddo M, Batson A G

出版信息

Br J Anaesth. 1985 Jun;57(6):550-3. doi: 10.1093/bja/57.6.550.

DOI:10.1093/bja/57.6.550
PMID:2408644
Abstract

This study was designed to determine the effects of a rapid bolus dose of atracurium 0.6 mg kg-1 on arterial pressure, heart rate and plasma histamine concentration (n = 9), and to compare these values with those obtained by (a) giving the same dose of atracurium slowly (over 75 s) (n = 9), or (b) pre-treating with H1- and H2- antagonists (n = 9). The rapid (5-s) bolus dose of atracurium i.v. resulted in a significant increase in plasma histamine concentration (P less than 0.05) and was associated with a decrease in mean arterial pressure and an increase in heart rate. Administering the same dose of atracurium slowly (over 75 s) prevented the increase in plasma histamine concentration, and abolished the subsequent haemodynamic response. Pretreatment with cimetidine 4 mg kg-1 i.v. and chlorpheniramine 0.1 mg kg-1 i.v. abolished the haemodynamic response despite a moderate increase in histamine concentration (0.1 greater than P greater than 0.05).

摘要

本研究旨在确定快速推注剂量为0.6毫克/千克的阿曲库铵对动脉压、心率和血浆组胺浓度的影响(n = 9),并将这些值与以下情况获得的值进行比较:(a) 缓慢给予相同剂量的阿曲库铵(超过75秒)(n = 9),或 (b) 用H1和H2拮抗剂进行预处理(n = 9)。静脉内快速(5秒)推注阿曲库铵导致血浆组胺浓度显著升高(P < 0.05),并伴有平均动脉压降低和心率增加。缓慢(超过75秒)给予相同剂量的阿曲库铵可防止血浆组胺浓度升高,并消除随后的血流动力学反应。静脉内给予西咪替丁4毫克/千克和氯苯那敏0.1毫克/千克进行预处理,尽管组胺浓度有适度升高(0.1 > P > 0.05),但仍消除了血流动力学反应。

相似文献

1
Atracurium: clinical strategies for preventing histamine release and attenuating the haemodynamic response.阿曲库铵:预防组胺释放及减轻血流动力学反应的临床策略。
Br J Anaesth. 1985 Jun;57(6):550-3. doi: 10.1093/bja/57.6.550.
2
Clinical pharmacology of atracurium given in high dose.
Br J Anaesth. 1986 Aug;58(8):834-8. doi: 10.1093/bja/58.8.834.
3
Histamine-release haemodynamic changes produced by rocuronium, vecuronium, mivacurium, atracurium and tubocurarine.罗库溴铵、维库溴铵、米库氯铵、阿曲库铵和筒箭毒碱引起的组胺释放血流动力学变化。
Br J Anaesth. 1995 Nov;75(5):588-92. doi: 10.1093/bja/75.5.588.
4
Plasma histamine levels following atracurium.
Anaesthesia. 1986 Aug;41(8):821-4. doi: 10.1111/j.1365-2044.1986.tb13124.x.
5
Haemodynamic effects of atracurium in the presence of potent inhalation agents.强效吸入麻醉药存在时阿曲库铵的血流动力学效应。
Br J Anaesth. 1986;58 Suppl 1:70S-74S. doi: 10.1093/bja/58.suppl_1.70s.
6
[Hemodynamic effects of atracurium in man].[阿曲库铵对人体的血流动力学影响]
Ann Fr Anesth Reanim. 1985;4(6):484-8. doi: 10.1016/s0750-7658(85)80245-8.
7
Histamine-releasing potencies of atracurium, dimethyl tubocurarine and tubocurarine.阿曲库铵、二甲筒箭毒碱和筒箭毒碱的组胺释放效能。
Br J Anaesth. 1983;55 Suppl 1:105S-106S.
8
[Plasma histamine release following the intravenous administration of atracurium in man].
Masui. 1989 Feb;38(2):190-4.
9
Clinical comparison of atracurium and vecuronium (Org NC 45).阿曲库铵与维库溴铵(ORG NC 45)的临床比较。
Br J Anaesth. 1983 Feb;55(2):125-9. doi: 10.1093/bja/55.2.125.
10
Circulatory effects of atracurium in patients with cardiovascular disease.阿曲库铵对心血管疾病患者的循环系统影响。
Br J Anaesth. 1986;58 Suppl 1:83S-88S. doi: 10.1093/bja/58.suppl_1.83s.

引用本文的文献

1
Caffeine Acts as an Agonist of Siglec-6, Inhibits MRGPRX2-Triggered Mast Cell Degranulation and Anaphylactoid Reactions.咖啡因作为唾液酸结合免疫球蛋白样凝集素-6的激动剂,抑制MRGPRX2触发的肥大细胞脱颗粒和类过敏反应。
Mediators Inflamm. 2025 Aug 30;2025:9580121. doi: 10.1155/mi/9580121. eCollection 2025.
2
Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system.与神经肌肉阻滞剂相关的不良事件:美国食品药品监督管理局不良事件报告系统的不成比例分析
Front Pharmacol. 2024 Jul 24;15:1403988. doi: 10.3389/fphar.2024.1403988. eCollection 2024.
3
Atracurium-Induced Bronchospasm With Flat Capnograph at Induction of General Anaesthesia: A Case Report.
全身麻醉诱导时阿曲库铵所致支气管痉挛伴二氧化碳波形图平坦:一例报告
Cureus. 2024 Feb 15;16(2):e54251. doi: 10.7759/cureus.54251. eCollection 2024 Feb.
4
MRGPRX2 and Adverse Drug Reactions.MRGPRX2 与药物不良反应。
Front Immunol. 2021 Aug 6;12:676354. doi: 10.3389/fimmu.2021.676354. eCollection 2021.
5
The Incidence of hypotension with continuous infusion atracurium compared to cisatracurium in the Intensive Care Unit.重症监护病房中持续输注阿曲库铵与顺式阿曲库铵相比低血压的发生率。
Int J Crit Illn Inj Sci. 2017 Apr-Jun;7(2):113-118. doi: 10.4103/IJCIIS.IJCIIS_35_16.
6
Chirality and anaesthetic drugs: A review and an update.手性与麻醉药物:综述与更新
Indian J Anaesth. 2011 Nov;55(6):556-62. doi: 10.4103/0019-5049.90608.
7
Adverse effects of neuromuscular blockers and their antagonists.神经肌肉阻滞剂及其拮抗剂的不良反应。
Drug Saf. 1998 Feb;18(2):99-116. doi: 10.2165/00002018-199818020-00002.
8
Anaesthesia in the elderly. Special considerations.老年人的麻醉。特殊注意事项。
Drugs Aging. 1996 Nov;9(5):319-31. doi: 10.2165/00002512-199609050-00003.
9
Adverse effects of nondepolarising neuromuscular blocking agents. Incidence, prevention and management.非去极化神经肌肉阻滞剂的不良反应。发生率、预防及处理
Drug Saf. 1994 Jun;10(6):420-38. doi: 10.2165/00002018-199410060-00002.
10
New intravenous anaesthetics and neuromuscular blocking drugs. A review of their properties and clinical use.新型静脉麻醉药和神经肌肉阻滞药。其特性及临床应用综述。
Drugs. 1987 Jul;34(1):98-135. doi: 10.2165/00003495-198734010-00004.